title: Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review.
abstract: Intravesical instillation of Bacillus Calmette-Guerin (BCG) is used with efficacy and safety in the treatment of patients with intermediate and high-risk superficial bladder carcinoma. Arthralgia and/or arthritis is one of the rare severe complications following intravesical BCG immunotherapy. We searched MEDLINE in order to analyze the frequency of this clinical complication, its pathogenesis and outcome. The electronic search was conducted using the following key words: "BCG immunotherapy" and "Arthritis, arthralgias and BCG immunotherapy". At the end of a process of abstract analysis, 48 papers were included in the systematic review. All the selected papers, except one that was a clinical review, described at least one case of arthritis after BCG therapy. The BCG immunotherapy resulted to be safe and efficacious in the treatment of bladder cancer; the development of reactive arthritis is rare and can evolve in a chronic process. The review of the literature highlighted that reactive arthritis following BCG intravesical instillation is a complication usually well controlled with the discontinuation of the immunotherapy and nonsteroidal anti-inflammatory drugs (NSAIDs) treatment. Only a small portion of patients with a particular genetic background will develop a chronic process.
authors.affiliation: Department of Clinical and Experimental Medicine, Section of Internal Medicine, University of Verona, Policlinico G. B. Rossi, P.le L. A. Scuro, 10, 37134, Verona, Italy.
authors.forename: Elisa
authors.initials: E
authors.lastname: Tinazzi
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Ficarra
authors.forename: Sara
authors.initials: S
authors.lastname: Simeoni
authors.forename: Walter
authors.initials: W
authors.lastname: Artibani
authors.forename: Claudio
authors.initials: C
authors.lastname: Lunardi
mesh_terms: D000283:Administration, Intravesical; D016918:Arthritis, Reactive / Q000209:etiology* / Q000503:physiopathology; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects*; D002277:Carcinoma / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D018448:Models, Immunological; D018716:Molecular Mimicry; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D001500:BCG Vaccine